Stevanato Group (NYSE:STVN) Sets New 1-Year Low at $21.25

Shares of Stevanato Group S.p.A. (NYSE:STVN) hit a new 52-week low on Thursday . The stock traded as low as €21.25 ($22.85) and last traded at €22.48 ($24.17), with a volume of 381924 shares. The stock had previously closed at €26.91 ($28.94).

Analysts Set New Price Targets

Several brokerages have weighed in on STVN. BNP Paribas initiated coverage on shares of Stevanato Group in a report on Monday, April 22nd. They set an “outperform” rating for the company. Stephens reiterated an “overweight” rating and issued a $38.00 price objective on shares of Stevanato Group in a research report on Monday, March 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $30.00 price objective on shares of Stevanato Group in a research report on Monday, April 22nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of €34.29 ($36.87).

Stevanato Group Stock Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 1.50 and a quick ratio of 1.06. The firm has a market capitalization of $6.15 billion, a P/E ratio of 36.05, a P/E/G ratio of 2.92 and a beta of 0.76. The stock’s 50 day moving average is €29.36 and its two-hundred day moving average is €29.04.

Stevanato Group (NYSE:STVN) last released its quarterly earnings results on Thursday, March 7th. The company reported €0.18 ($0.19) earnings per share for the quarter, missing the consensus estimate of €0.19 ($0.20) by (€0.01) (($0.01)). Stevanato Group had a net margin of 13.43% and a return on equity of 14.31%. The company had revenue of €320.60 million during the quarter, compared to analyst estimates of €326.85 million. During the same quarter last year, the company earned $0.19 EPS. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. As a group, equities analysts anticipate that Stevanato Group S.p.A. will post 0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

Several large investors have recently modified their holdings of the stock. Raymond James & Associates increased its holdings in Stevanato Group by 0.9% in the 3rd quarter. Raymond James & Associates now owns 197,316 shares of the company’s stock valued at $5,864,000 after buying an additional 1,806 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stevanato Group in the 3rd quarter valued at approximately $255,000. Conestoga Capital Advisors LLC boosted its stake in shares of Stevanato Group by 19.7% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 4,534,088 shares of the company’s stock valued at $134,753,000 after purchasing an additional 746,136 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Stevanato Group by 70.1% in the 3rd quarter. Fifth Third Bancorp now owns 2,473 shares of the company’s stock valued at $73,000 after purchasing an additional 1,019 shares in the last quarter. Finally, Sivik Global Healthcare LLC boosted its stake in shares of Stevanato Group by 8.7% in the 3rd quarter. Sivik Global Healthcare LLC now owns 76,072 shares of the company’s stock valued at $2,261,000 after purchasing an additional 6,072 shares in the last quarter.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.